Inactive

The Centers for Disease Control and Prevention intends to award a sole source firm fixed price contract modification under contract 75D30122D13472 to Merck Sharp & Dohme LLC (Merck) for the Vaxneuvanc... The Centers for Disease Control and Prevention intends to award a sole source firm fixed price contract modification under contract 75D30122D13472 to Merck Sharp & Dohme LLC (Merck) for the Vaxneuvance (PCV15) vaccine. On June 22, 2022, the Advisory Committee for Immunization Practices (ACIP) approved recommendations related to pneumococcal vaccines for children. PCV15 (Merck’s Vaxneuvance) may be routinely recommended to US infants and children, including routine use in children under 2 years of age. Vaxneuvance vaccine from Merck is the only vaccine being considered for this request. Currently, there is only one manufacturer with an FDA-approved license for PCV15 at this time – Merck. The current Merck contract will be modified to include doses to support the ACIP recommendation that US infants and children 6 weeks through 17 years of age receive PCV15. This contract action is for supplies or services for which the Government intends to solicit and negotiate with only one source under the authority of FAR 6.302-1 and 41 U.S.C. 3304(a)(1). Interested persons may identify their interest and capability to respond to the requirement or submit proposals. This notice of intent is not a request for competitive quotations; however, all quotations/responses received within fifteen (15) days of the issuance of this notice will be considered by the government. A determination by the government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the government. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement. Any quotation/response should be emailed to Christina McMichael at wpn6@cdc.gov by 5:00 PM EST on August 20, 2022.